Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 153.03% | 188.23% | 100.12% | 81.97% | -5.66% |
| Total Depreciation and Amortization | -9.02% | -7.30% | -3.14% | 30.40% | 32.12% |
| Total Amortization of Deferred Charges | -73.57% | -33.10% | 24.06% | 106.58% | 145.38% |
| Total Other Non-Cash Items | -502.10% | -374.78% | -354.24% | -315.73% | -38.99% |
| Change in Net Operating Assets | 21.32% | -39.50% | -11.08% | -29.88% | -140.00% |
| Cash from Operations | 67.03% | -13.76% | -26.63% | -28.09% | -47.72% |
| Capital Expenditure | 84.69% | 91.13% | 95.24% | 88.95% | 71.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -88.08% | -92.45% | -94.99% | -97.98% |
| Cash from Investing | 9,921.34% | 1,729.08% | 1,244.67% | 713.95% | -102.42% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -141.97% | -141.97% | -141.97% | 100.00% |
| Issuance of Common Stock | -25.09% | -41.82% | 77.15% | 162.66% | -77.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -505.32% | -227.29% | -226.03% | -222.62% | -84.00% |
| Foreign Exchange rate Adjustments | -200.00% | -150.00% | -150.00% | -100.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.72% | -414.06% | -175.74% | -185.75% | -252.49% |